Recruitment

Recruitment Status
Recruiting
Estimated Enrollment
135

Summary

Conditions
  • Lewy Body Disease
  • Mild Cognitive Impairment
  • Mild Dementia
  • Parkinson Disease
Type
Interventional
Phase
Phase 2
Design
Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Triple (Participant, Investigator, Outcomes Assessor)Primary Purpose: Treatment

Participation Requirements

Age
Between 50 years and 80 years
Gender
Both males and females

Description

The study will be a 16 to 18-week study, including a 2 to 4-week screening period, followed by a 12-week double-blind, randomized, placebo-controlled treatment Period, and a 2-week follow-up period. Subjects eligible for the study will be randomized to receive either NYX-458 or placebo.

The study will be a 16 to 18-week study, including a 2 to 4-week screening period, followed by a 12-week double-blind, randomized, placebo-controlled treatment Period, and a 2-week follow-up period. Subjects eligible for the study will be randomized to receive either NYX-458 or placebo.

Tracking Information

NCT #
NCT04148391
Collaborators
  • CogState Ltd.
  • Worldwide Clinical Trials
Investigators
Not Provided